- Eleutheroside E
-
- $0.00 / 1KG
-
2025-06-30
- CAS:39432-56-9
- Min. Order: 1KG
- Purity: 0.8%-80% TLC
- Supply Ability: 1000KG
- Eleutheroside E
-
- $56.00 / 10mg
-
2025-06-19
- CAS:39432-56-9
- Min. Order:
- Purity: 98.69%
- Supply Ability: 10g
- Eleutheroside E
-
- $0.00 / 20mg
-
2023-02-24
- CAS:39432-56-9
- Min. Order: 5mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
|
| | Eleutheroside E Basic information |
| Product Name: | Eleutheroside E | | Synonyms: | Eleutheroside;b-D-Glucopyranoside,[(1R,3aR,4S,6aS)-tetrahydro-1H,3H-furo[3,4-c]furan-1,4-diyl]bis(2,6-diMethoxy-4,1-phenylene)bis-;[(1R,3aR,4S,6aS)-Tetrahydro-1H,3H-furo[3,4-c]furan-1,4-diyl]bis(2,6-dimethoxy-4,1-phenylene) bis-β-D-glucopyranoside;ELEUTHEROSIDE E;(-)-SYRINGARESINOL DIGLUCOSIDE;(2R,3S,4R,5R,6S)-2-[4-[4-[3,5-Dimethoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-1,3,3a,4,6,6a-hexahydrofuro[4,3-c]furan-1-yl]-2,6-dimethoxyphenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol;Related CAS No: 19046-36-7 96038-87-8 66791-77-3;Manyprickle Acathopanax Root | | CAS: | 39432-56-9 | | MF: | C34H46O18 | | MW: | 742.72 | | EINECS: | 609-679-3 | | Product Categories: | pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;chemical reagent;Coumarins | | Mol File: | 39432-56-9.mol |  |
| | Eleutheroside E Chemical Properties |
| Melting point | 269～270℃ | | Boiling point | 935.7±65.0 °C(Predicted) | | density | 1.474±0.06 g/cm3(Predicted) | | storage temp. | Sealed in dry,2-8°C | | solubility | DMSO (Slightly), Ethyl Acetate (Slightly), Pyridine (Slightly, Sonicated) | | pka | 12.45±0.70(Predicted) | | form | Solid | | color | White to Off-White | | Stability: | Hygroscopic |
| Hazard Codes | Xn | | Risk Statements | 22 | | Safety Statements | 24/25 | | WGK Germany | 3 | | HS Code | 29389090 |
| | Eleutheroside E Usage And Synthesis |
| Uses | Eleutheroside E is used in the treatment of collagen-induced arthritis. Used in the suppression of inflammatory cytokine release. Successful in the treatment of rheumatoid arthritis. Also used in the regulation of adipogenesis | | Definition | ChEBI: Eleutheroside E is a lignan and a glycoside. | | in vivo | Eleutheroside E (0.003%, oral, daily, for five weeks) improves liver glucose metabolism in obese type 2 diabetes mice by upregulating glycolysis and downregulating gluconeogenesis[1].
Eleutheroside E (15-60 mg/kg, oral, once daily, three weeks) alleviates arthritis in a collagen-induced arthritis mouse model[3].
Eleutheroside E (50 mg/kg, oral, once daily, four weeks) prevents cognitive deficits caused by radiation in mice[4]. | Animal Model: | db/db mice[1] | | Dosage: | Containing 0.003% of the diet; 5 weeks | | Administration: | Oral | | Result: | Improved blood lipids, significantly reduced blood sugar and serum insulin levels, induced HOMA-IR, increased insulin sensitivity, and protected pancreatic α and β cells from diabetic damage. |
| Animal Model: | Collageninduced arthritis (CIA) mice[3] | | Dosage: | 15, 30, 60 mg/kg; daily; 3 weeks | | Administration: | Oral | | Result: | Reduced mean arthritis score and arthritis incidence, reduced inflammatory cell infiltration, mesenchymal formation, cartilage damage and bone erosion in CIA mice, and decreased TNF-α and IL-6. |
| Animal Model: | Mice irradiated with 60Co-γ rays[4] | | Dosage: | 50 mg/kg; daily; 4 weeks | | Administration: | Oral | | Result: | Improved cognitive and spatial memory impairments in irradiated mice, protected hippocampal neurons, and activated the PKA/CREB/BDNF signaling pathway. |
| | target | NF-kB | TNF-α | IL Receptor | P450 (e.g. CYP17) | IFN-γ |
| | Eleutheroside E Preparation Products And Raw materials |
|